Clinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, United States
Auto-generated profile, based on publicly available information
Kelly K. Filipski
Clinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, United States
An important and often overlooked subpopulation of cancer survivors is individuals who are diagnosed with or progress to advanced or metastatic cancer. Living longer with advanced or metastatic cancer often comes with a cost of burdensome physical and psychosocial symptoms and complex care needs; however, research is limited on this population. Thus, in May 2021, the National Cancer Institute convened subject matter experts, researchers, clinicians, survivors, and advocates for a 2-day virtual meeting. The purpose of this report is to provide a summary of the evidence gaps identified by subject matter experts and attendees and key opportunities identified by the National Cancer Institute in 5 research areas: epidemiology and surveillance, symptom management, psychosocial research, health-care delivery, and health behaviors. Identified gaps and opportunities include the need to develop new strategies to estimate the number of individuals living with advanced and metastatic cancers; understand and address emerging symptom trajectories; improve prognostic understanding and communication between providers, patients, and caregivers; develop and test models of comprehensive survivorship care tailored to these populations; and assess patient and provider preferences for health behavior discussions throughout the survivorship trajectory. To best address the needs of individuals living with advanced and metastatic cancer and to deliver comprehensive evidence-based quality care, research is urgently needed to fill evidence gaps, and it is essential to incorporate the survivor perspective. Developing such an evidence base is critical to inform policy and practice.
4 March 2025 in Cancer Epidemiology, Biomarkers & Prevention
Background: The goal of this article was to provide an overview of the current NCI-funded large cancer epidemiology survivor cohorts (CESC). Methods: Large CESCs were defined as observational cohort studies following at least 1,000 cancer survivors over time and collecting data on survivorship outcomes. CESCs with NCI grant funding on June 1, 2024 were identified in two ways: (i) by identifying grants funded under cancer epidemiology cohort–relevant Notice of Funding Opportunities and (ii) by applying the Research, Condition, and Disease Categorization–indexed concepts related to cohorts to the entire NCI grant portfolio in the NIH’s proprietary Query, View, Reporting System and reviewing grants identified via this search for inclusion. Results: Thirty active grants supporting large CESCs were identified. Of the 30 CESCs, 36.7% are comprised of survivors of mixed cancer types; the remaining 63.3% are following survivors diagnosed with cancer of a single anatomic type or grouping (e.g., blood cancers). Special populations of focus include adult survivors of pediatric cancers, adolescent and young adult cancer survivors, pediatric cancer survivors, and stem cell transplant survivors. Notable gaps include cohorts following long-term cancer survivors, survivors of less common cancer types, and survivors from understudied populations. Conclusions: CESCs highlighted in this article represent a substantial investment in exploring the multifaceted factors that influence cancer outcomes. These cohorts encompass an increasing diversity of cancer types, treatments, and populations. Impact: CESCs provide valuable insights into clinical and molecular risk factors associated with cancer survivorship outcomes that inform guidelines and interventions.
1 March 2022 in Cancer Epidemiology, Biomarkers & Prevention
Since the late 19th century, the immune system has been known to play a role in cancer risk, initiation, and progression. Genome-wide association studies (GWAS) have identified hundreds of genetic risk loci for autoimmune and inflammatory diseases, yet the connection between human genetic variation and immune-mediated response to cancer treatments remains less well-explored. Understanding inherited genetic variation, with respect to germline genetic polymorphisms that affect immune system pathways, could lead to greater insights about how these processes may best be harnessed to successfully treat cancer. Our goal in this manuscript was to understand progress and challenges in assessing the role of inherited genetic variation in response to cancer treatments. Overall, the 39 studies reviewed here suggest that germline genetic variation in immune system–related genes may potentially affect responses to cancer treatments. Although further research is needed, considering information on germline immune genetic variation may help, in some cases, to optimize cancer treatment.
13 March 2021 in Pharmacoepidemiology and Drug Safety
The advent of the genomic age has created a rapid increase in complexity for the development and selection of drug treatments. A key component of precision medicine is the use of genetic information to improve therapeutic effectiveness of drugs and prevent potential adverse drug reactions. Pharmacoepidemiology, as a field, uses observational methods to evaluate the safety and effectiveness of drug treatments in populations. Pharmacoepidemiology by virtue of its focus, tradition, and research orientation can provide appropriate study designs and analysis methods for precision medicine. The objective of this manuscript is to demonstrate how pharmacoepidemiology can impact and shape precision medicine and serve as a reference for pharmacoepidemiologists interested in contributing to the science of precision medicine. This paper depicts the state of the science with respect to the need for pharmacoepidemiology and pharmacoepidemiological methods, tools and approaches for precision medicine; the need for and how pharmacoepidemiologists use their skills to engage with the precision medicine community; and recommendations for moving the science of precision medicine pharmacoepidemiology forward. We propose a new integrated multidisciplinary approach dedicated to the emerging science of precision medicine pharmacoepidemiology.
26 February 2026 in JNCI: Journal of the National Cancer Institute
Cannabis use for symptom management among patients with cancer has increased in recent years, with many reporting benefits for pain, anxiety, sleep, nausea, and appetite, as well as other symptoms. However, rigorous prospective data on the potential benefits and harms of cannabis use in this population are lacking. This commentary describes a US National Cancer Institute–led initiative addressing this research gap by supporting 5 prospective observational studies evaluating the benefits and harms of cannabis use among a large heterogeneous sample of patients with cancer undergoing active systemic treatment. We provide an overview of each study, including cancer type, treatment modalities, inclusion and exclusion criteria, data collection methods, and patient-reported and cancer-related outcomes.
Background:The goal of this article was to provide an overview of the current NCI-funded large cancer epidemiology survivor cohorts (CESC).Methods:Large CESCs were defined as observational cohort studies following at least 1,000 cancer survivors over time and collecting data on survivorship outcomes. CESCs with NCI grant funding on June 1, 2024 were identified in two ways: (i) by identifying grants funded under cancer epidemiology cohort–relevant Notice of Funding Opportunities and (ii) by applying the Research, Condition, and Disease Categorization–indexed concepts related to cohorts to the entire NCI grant portfolio in the NIH’s proprietary Query, View, Reporting System and reviewing grants identified via this search for inclusion.Results:Thirty active grants supporting large CESCs were identified. Of the 30 CESCs, 36.7% are comprised of survivors of mixed cancer types; the remaining 63.3% are following survivors diagnosed with cancer of a single anatomic type or grouping (e.g., blood cancers). Special populations of focus include adult survivors of pediatric cancers, adolescent and young adult cancer survivors, pediatric cancer survivors, and stem cell transplant survivors. Notable gaps include cohorts following long-term cancer survivors, survivors of less common cancer types, and survivors from understudied populations.Conclusions:CESCs highlighted in this article represent a substantial investment in exploring the multifaceted factors that influence cancer outcomes. These cohorts encompass an increasing diversity of cancer types, treatments, and populations.Impact:CESCs provide valuable insights into clinical and molecular risk factors associated with cancer survivorship outcomes that inform guidelines and interventions.